bactericidal, suffer from various drawbacks, such as an increased emergence of resistant M. leprae to dapsone, 2 skin discolouration with the use of c1ofazimine, 3 -5 and the hepatotoxicity of thiomides. 6 , 7 Even resistance to rifampicin, has been reported. 8 , 9 Hence there is an urgent need to search for newer more potent bactericidal drugs, the detection of which might also help in reducing the duration of treatment. Several fluoroquinolones, especially ofloxacin, were found to be most active against M. leprae in vitro lO and in vivo. ll
Limited clinical trials concluded with ofloxacin and pefloxacin alone or in combina tion with other drugs reported highly fa vourable results in terms of tolerance, side effects, clinical improvement and reduction in viable M. leprae. 12 , 13 A randomized clinical trial in lepromatous leprosy patients administered regimens containing dapsone, c10fazimine and ofloxacin, has been conducted to find out the rate of kill of M. leprae in the mouse fo otpad model, the clinical response and the side-effects to drugs, and the results are reported below.
Materials and methods
A total of 26 clinically diagnosed, adult patients with active, untreated lepromatous leprosy were admitted to the hospital of the Central Leprosy Teaching and Research Institute, Chengalpattu, India, between September 1989 and December 1991. As well as close questioning on their first examination, a urine spot test for dapsone was conducted and we estimated their creatinine-dapsone ratio, to establish each patient's treatment status at intake. The procedures laid down in the standard THELEP protocol for examination, investigation and documentation of lepromatous leprosy patients were fo llowed. After a thorough examination, patients received slit-skin smears for the bacteriological index (BI) and the morphological index (MI), and routine blood, urine and stool examinations, a skiagram of the chest, a lepromin test, and liver and kidney function tests were carried out. Biopsies were collected from sites with BI � 4+ for mouse fo otpad (MFP) inoculation and histopathology. Patients with either a history of ENL reactions or who had complications with other diseases such as diabetes and tuberculosis, or were over 65 years, or pregnant women were excluded from the study. Patients were allocated randomly in groups of 3 14 to the 3 regimens, namely: 1, c10fazimine 300 mg once in 4 weeks and 50 mg daily + dapsone 100 mg daily for 56 days (AA regimen); 2, AA regimen + 400 mg of ofloxacin daily for 56 days (BB regimen); and 3, AA regimen + 800 mg of ofloxacin daily for 56 days (CC regimen). Biopsies were collected from each of the patients on day 0, 7, 14, 28 and 56 of treatment from the same site. After processing, biopsy suspensions were inoculated into both hind footpads of each mouse in dilutions of 10 4 , 10 3 , 10 2 and 10 1 using 10 normal albino mice aged 6-8 weeks for each dilution, duly fo llowing Shepard's technique. Harvesting of fo otpads was done 1 year after inoculation. Smear BI and MI examination was repeated on day 28 and 56. Liver and kidney function tests and other haematological examinations were repeated at each biopsy. Prescribed drugs were administered daily under supervision and clinical progress was documented. The presence of � 10 5 organisms per fo otpad on harvesting was taken as positive for growth in MFP. The calculation for arriving at the proportion of viable organisms through the analysis of median infectious doses (ID 5 0 ) and significance were made as described in Laboratory techniques in leprosy published by WHO.I 5 If no growth had been detected after the commence�ent of t�e chemotherapy, it was assumed that growth had occurred in a fo otpad inoculated with the maximum concentration of inoculum for arriving at the probable proportion of the viable organism. The difference in proportion of the viable organism distribution in different regimens on day 0, median percentage of kill on day 7 between regimens and the frequency of significant reduction at day 7 were tested by Mann-Whitney and Fisher's exact tests for significance. Comparisons were not made f9r frequency of significant reduction beyond day 7. Clinical improvement was judged by flattening of the nodules, regression of infiltration, clearance of erythema and improvement in nasal congestion, etc. All the cases were put on the WHO recommended multidrug treatment regimen for MB patients on completion of the 56 days of trial. The study was not blind.
Results

PROPORTION OF VIABLE ORGANISMS, GROWTH IN MFP AND PERCENTAGE OF KILL
Of the 26 cases taken into the study, 3 cases (case nos 5, 11 and 12) were females and 3 were BL histopathologically (case nos 2, 5 and 15). Case no. 22 dropped out from trial after day 28. The number of MFP harvested and found positive for growth is given in Table 1 . No growth was detected from day 0 of biopsy inocul'ation in 7 cases (case nos 1, 4, 5, 11, 12, 14 and 18) and hence they were excluded from analysis. The growth in MFP has been found to be negative in all patients treated with CC regimen by day 28 and with BB regimen by day 56 (Figure 1 ), whereas the growth was fo�nd positive in 1 patient on day 56 with AA regimen. However, 1 case under BB regimen showed growth in 1 MFP among 40 harvested at day 14 and 1 of 64 harvested at day 2�, after attaining negativity at day 7 during the course of treatment (case no. 8).
The proportion of viable organisms, in general, was found to be very low on day 0, though inoculations were made from biopsy suspensions from sites showing BI � 4+. There were wide variations in the proportion of viable organisms in all the regimens. Despite randomization of patients in groups of 3, there were significant differences between the medians of proportion of viable organisms among the regimens at day 0, being highest in AA regimen (Table 2 ). It is observed that the lower the proportion of viable organisms on day 0, the less was the percentage of organisms killed by day 7 with any of the regimens. The maximum kill has occurred between day 0 and 7 in BB and CC regimens. The median percentage of kill has been found to be significantly higher in 'BB and CC regimens when compared to AA regimen ( Table 2 ). The frequency of significant reduction of proportion of viable organisms on day 7 apparently appears to be more in BB and CC regimens compared to AA. The precise estimation of percentage of kin beyond day 7 could not be made in BB and CC regimens because no growth occurred in the footpad in most of the cases, which is perhaps due to very low proportion of viable organisms at day o. MI and BI on day 0, 28 and 56 is shown in Table 3 . In general MI at intake of cases was found to be low and even 0 in 9 cases. There has been consistent fall in MI ' in all the cases with progress of treatment. In 11 out of 17 cases (64·7%) the MI has reached 0·0% by day 56. No significant differences were noticed in the fall of MI between the regimens.
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COMPLICATIONS AND SIDE-EFFECTS
Complications in the form of mild Type I and II reactions and neuritis; and side-effects to drugs such as headache, giddiness, pain in the legs, vomiting, pain in the abdomen, loose stools and itching occurred in more patients treated with BB and CC regimens, compared to AA, but the differences were not significant. Complications responded to symptomatic treatment without steroids and drug side-effects were fo und to be mild and these cleared with the appropriate symptomatic treatment (Table 4 ). All the cases taken into the trial were analysed.
OTHER INVESTIGATIONS
No significant abnormalities were noticed in haematological and biochemical investiga tions at intake and during the course of trial.
Discussion
Loss of infectivity in MFP has been reported on administration of 28 daily doses of 400 mg ofloxacin in all untreated lepromatous leprosy patients. 1 3 The results of the present study indirectly corroborates the above findings with 800 mg of ofloxacin (CC), since growth positivity was noticed from biopsies treated with other regimens (BB and AA) on day 28 and beyond. But for the ambiguous MFP result of I patient in 'BB' regimen (case no. 8), a daily dose of 800 mg ofloxacin does not appear to be more active against M. leprae than 400 mg. A killing rate of M. leprae of > 99% has been reported with ofloxacin in normal mice by 28 daily does. 1 3 A lower rate of > 75% was noticed in the present study because of the very low proportion of viable organism in day 0 biopsy. The present duration of WHO recommended MDT treatment for MB patients for a minimum of 24 months was based on the fact that dapsone and clofazimine are weakly bactericidal in dealing with the possible rifampicin-resistant mutants. In view of the effectiveness of ofloxacin in making M. leprae non-infective in MFP by day 28 and the fast rate of kill, it should be theoretically possible to reduce the duration of therapy, if ofloxacin is added to the present WHO recommended MDT for MB leprosy. The MI appears to be useful only for monitoring the response to chemotherapy, since it was found to decline consistently with the progress of therapy. The fa ster clinical improvement noticed in patients who received ofloxacin-containing drug regimens has also been reported by others. 1 3 The slow clinical response with clofazimine l6 or dapsone is well known. Even when they were given together (AA) the majority (66'7%) of patients showed no clinical improvement.
Complications in the form of reactions and neuritis have not been reported by others either with ofloxacin or pefloxacin, but were noticed in the present study. 12 , 1 3 However, similar drug side-effects of a mild nature were reported as noticed in the present study, and the regimens were reported to have been well tolerated as in the present study.
Conclusions
The ofloxacin containing combined drug regimens were well tolerated by lepromatous leprosy patients. The complications and side-effects were of a mild nature. Moderate to marked clinical improvement was noticed in a short period with ofloxacin containing regimens. Ofloxacin if added to the currently used WHO recommended MB-MDT regimen may shorten the duration of treatment. Ofloxacin may be considered as a suitable alternative in suspected/proven rifampicin resistant cases and where rifampicin is contraindicted.
